Misabri Pr (Pregabalin)

Pregabalin is used across several neurological and psychiatric conditions where abnormal neuronal excitability is a key factor.

• Neuropathic pain: reduces pain intensity in diabetic peripheral neuropathy and post‑herpetic neuralgia.
• Partial onset seizures: provides adjunctive control of seizures in epilepsy.
• Generalized anxiety disorder: alleviates anxiety symptoms in adult patients.

• Pregabalin binds selectively to the α2‑δ subunit of voltage‑gated calcium channels in the central nervous system. This binding reduces calcium influx into presynaptic neurons, which in turn decreases the release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P, dampening neuronal hyper‑excitability associated with pain, seizures, and anxiety.

Pregabalin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Somnolence: increased sleepiness or fatigue.
• Peripheral edema: swelling of the lower extremities.
• Weight gain: gradual increase in body weight.
• Blurred vision: temporary visual disturbances.
• Dry mouth: reduced salivary flow.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips, tongue, or throat.
• Severe hypersensitivity reactions: rash, fever, or organ involvement.
• Suicidal thoughts or behavior: emergence of depressive symptoms.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Respiratory depression: especially when combined with other CNS depressants.
• Blood dyscrasias: rare cases of agranulocytosis or thrombocytopenia.

Before initiating therapy, clinicians should evaluate several safety considerations.

• Renal impairment: adjust dose based on creatinine clearance.
• Elderly patients: start at lower doses due to increased sensitivity.
• History of substance misuse: monitor for signs of dependence.
• Suicidal ideation: assess risk regularly during treatment.
• Pregnancy and lactation: use only if potential benefit justifies potential risk.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Pregabalin can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid)

• Opioids: combined use may cause profound sedation or respiratory depression.
• Benzodiazepines: increased risk of CNS depression and impaired coordination.
• Alcohol: additive sedative effects leading to excessive drowsiness.
• ACE inhibitors: may heighten risk of angioedema.
• Anticholinergic agents: can exacerbate cognitive impairment.

Moderate Interactions (Monitor Closely)

• Diuretics: may raise pregabalin plasma concentrations.
• NSAIDs: concurrent use can increase risk of renal dysfunction.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may elevate pregabalin levels.
• CYP3A4 inducers (e.g., carbamazepine): may reduce therapeutic effect.
• Antihistamines: may enhance dizziness or somnolence.